Enanta loses Federal Circuit appeal; Paxlovid patent claims invalidated

ENANTA PHARMACEUTICALS INC

Federal Circuit affirmed Dec 2024 summary judgment, ruling claims of U.S. Patent No. 11,358,953 invalid.
Patent covered Pfizer's COVID-19 antiviral Paxlovid (nirmatrelvir; ritonavir).
Enanta had sought damages for infringement; appeal loss eliminates potential royalty stream.
Decision issued on June 23, 2026 by the U.S. Court of Appeals for the Federal Circuit.

Featured in Daily 8-K Digest

Selected #6 for 2026-06-23. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.